Sutro Biopharma, Inc. - Common Stock (STRO)
Frequently Asked Questions About Sutro Biopharma, Inc. - Common Stock (STRO)
Does Sutro Biopharma have any collaborations or partnerships?
Yes, Sutro Biopharma has engaged in various collaborations with pharmaceutical companies for the development of its therapeutics. Such partnerships often involve sharing resources, expertise, and funding to accelerate the research and development process of promising therapies.
How can I stay updated on Sutro Biopharma's news and developments?
You can stay updated on Sutro Biopharma's news and developments by visiting the company's official website, subscribing to their press releases, following them on their social media platforms, and reviewing their filings with the SEC, which provide insights into their ongoing research and business operations.
How does Sutro Biopharma ensure the quality of its therapeutics?
Sutro Biopharma ensures the quality of its therapeutics by adhering to rigorous standards in research and development, manufacturing, and regulatory compliance. The company employs best practices in quality control and continuously monitors its processes to maintain high safety and efficacy standards.
Is Sutro Biopharma publicly traded?
Yes, Sutro Biopharma is publicly traded on the Nasdaq under the ticker symbol STRO. The company went public through an initial public offering (IPO) in 2019, allowing it to raise capital to support its ongoing research and development initiatives.
What are the potential markets for Sutro Biopharma's products?
Sutro Biopharma's products predominantly target the oncology market, which has a significant unmet need for innovative, effective treatments. The company aims to address various forms of cancer with its ADCs and is positioned to participate in the growing demand for advanced cancer therapies.
What are the risks associated with investing in Sutro Biopharma?
Investing in Sutro Biopharma, like any biotech company, carries inherent risks. These may include the uncertainty of clinical trial outcomes, the potential need for additional funding, market competition, regulatory challenges, and the company's ability to successfully commercialize its product candidates.
What does Sutro Biopharma, Inc. do?
Sutro Biopharma, Inc. is a clinical-stage biotechnology company that focuses on the development of next-generation antibody-drug conjugates (ADCs) and other biotherapeutics for the treatment of cancer. The company's proprietary technology platform allows for the rapid and efficient design, production, and characterization of custom proteins and therapeutics.
What financial information is publicly available for Sutro Biopharma?
As a publicly traded company, Sutro Biopharma is required to file regular reports with the U.S. Securities and Exchange Commission (SEC), including quarterly and annual filings that disclose financial performance, operational updates, and other material information pertinent to investors.
What is Sutro Biopharma's long-term vision?
Sutro Biopharma's long-term vision is to be a leader in the field of biopharmaceuticals by developing groundbreaking therapies that improve the lives of cancer patients. The company aims to expand its pipeline, innovate its technology, and establish partnerships that enhance its growth and therapeutic portfolio.
What is Sutro's approach to drug development?
Sutro Biopharma adopts a patient-centric approach to drug development, focusing on creating therapies that meet specific unmet medical needs in oncology. By leveraging its proprietary technology, the company aims to develop targeted therapies that can provide more effective and safer treatment options for cancer patients.
What is the current status of Sutro Biopharma's pipeline?
Sutro Biopharma has several clinical-stage programs under development. The company’s lead product candidates include STRO-001, an ADC targeting CD74, and STRO-002, an ADC targeting folate receptor alpha (FRα). These candidates are in various stages of clinical trials aimed at assessing their safety and efficacy in patients.
What is the mission of Sutro Biopharma?
The mission of Sutro Biopharma is to transform patient lives through innovative biotherapeutics that target cancer cells more effectively while minimizing the impact on healthy tissues. The company is committed to advancing its pipeline of ADCs and other therapies to provide new options for patients with challenging malignancies.
What is the technology platform of Sutro Biopharma?
Sutro Biopharma utilizes a proprietary platform known as Xpress CF, which allows for the rapid and efficient production of complex proteins and antibody-drug conjugates. This technology enables the company to create highly optimized therapeutic candidates that are designed to maximize efficacy and minimize side effects.
What recent milestones has Sutro Biopharma achieved?
Sutro Biopharma has achieved several critical milestones, including advancing its lead drug candidates into clinical trials, reporting positive initial clinical data, and entering into strategic collaborations with larger pharmaceutical companies to enhance the development and commercialization of its product candidates.
What types of therapies is Sutro Biopharma developing?
Sutro Biopharma is primarily focused on developing antibody-drug conjugates and other protein-based therapies for various types of cancer. Their pipeline includes a range of therapeutic candidates designed to target specific cancer cells while sparing healthy tissue, thus improving safety profiles for patients.
When was Sutro Biopharma founded?
Sutro Biopharma was founded in 2003. Since its inception, the company has been dedicated to advancing innovative therapeutic solutions for patients with cancer by utilizing its proprietary protein engineering and manufacturing technology.
Where is Sutro Biopharma headquartered?
Sutro Biopharma is headquartered in South San Francisco, California. This location is strategically chosen to be in close proximity to a vibrant biotech ecosystem, providing access to talent, resources, and collaborative opportunities within the life sciences industry.
Who are the key executives at Sutro Biopharma?
Sutro Biopharma's executive team includes experienced leaders from the biotechnology and pharmaceutical industries. Key figures typically include the CEO, the Chief Medical Officer, and the Chief Financial Officer, all of whom bring significant expertise in drug development, corporate strategy, and operations.
What is the current price of Sutro Biopharma, Inc. - Common Stock?
The current price of Sutro Biopharma, Inc. - Common Stock is 0.5732
When was Sutro Biopharma, Inc. - Common Stock last traded?
The last trade of Sutro Biopharma, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Sutro Biopharma, Inc. - Common Stock?
The market capitalization of Sutro Biopharma, Inc. - Common Stock is 34.63M
How many shares of Sutro Biopharma, Inc. - Common Stock are outstanding?
Sutro Biopharma, Inc. - Common Stock has 60.42M shares outstanding.